EP
About
Over the course of the last decade, first as a graduate student at Harvard University in the Department of Molecular and Cell Biology with PhD advisor Professor Stuart Schreiber and then as an independent postdoctoral fellow at the Lewis-Sigler Institute at Princeton University, Dr. Ethan Perlstein developed an approach to studying old drugs and discovering new drugs in model organisms called evolutionary pharmacology. Ethan is an author on 19 peer-reviewed scholarly publications, including the discovery of a novel mechanism of action for the antidepressant Zoloft based on studies in yeast cells.
Position in the VCSift Database
- • 3,360 investors hold the CEO role in VCSift. Ethan Oren Perlstein is one of them.
- • 7,285 investors are based in San Francisco, California, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Stages
- seed
- Location
- San Francisco, US
Contact Information
linkedin.com/in/••••••••
Find more investors like Ethan Oren
Search Investors